Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma

Volume: 29 Number: 2 April 1, 2016
  • Burcak Erkol
  • Fugen Aker
  • Zeynep Gamze Kılıcoglu
  • Basak Ustaalioglu
  • Tarık Salman
EN TR

Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma

Abstract

Peritoneal mesotheliomas are aggressive tumors arising from the peritoneal mesothelium. Tumor markers are biochemical substancesproduced by tumor cells due to the effect of malignant process. They can be used for screening, diagnosis, and predicting the prognosis. β-human chorionic β-human chorionic gonadotrophin (β-hCG), is a marker of germ cell tumors and trophoblastic diseases. In some reports, a relationship between β-hCG and other malignant diseases has been described. Hereby, we present a case of malignant peritoneal mesothelioma associated withelevated serum β-hCG levels. A 49-year-old man was admitted to the hospital with ascites. Peritoneal mesothelioma was diagnosed with peritoneal biopsy. During the treatment period, serum β-hCG levels were elevated together with disease progression and tissue samples stained positive for β-hCG. Rising levels of serum β-hCG due to disease progression can predict the response to treatment. If these levels were elevated at the beginning of the treatment, it may be a prognostic marker for peritoneal mesothelioma. Thus, β-hCG may be an important marker for prognosis or prediction of treatment for peritoneal mesothelioma patients.Keywords: Mesothelioma, Human chorionic gonadotrophin,Tumor marker

References

  1. Raptopoulos V. Peritoneal mesothelioma. Crit Rev Diagn Imaging 1985;24:293-328.
  2. Selvam NT, Elumalai P, Venkatakrishnan V, Damodarkumar S. Molecular markers in cancer diagnosis and management: A Review. JAppl Biol Sci 2011;5: 69-74. doi: 10.1002/iso.21787
  3. Hussa RO. The clinical marker hCG. New York: Praeger, 1987.doi: 10.1038/modpathol.3800086
  4. Berhil H, Chenna H, Nouni K, et al. Malignant mesothelioma of peritoneum: about a case with review of the literature. J Cancer Sci Ther 2012;4:235-6. doi:10.4172/1948-5956.1000147
  5. Rich S, Presant CA, Meyer J, Stevens SC, Carr D. Human chorionic gonadrotropin and malignant mesothelioma. Cancer 1979; 43: 1457-62.
  6. Okamoto H, Matsuno Y, Noguchi M, et al.Malignant pleural mesothelioma producing human chorionic gonadotropin. Am J Surg Pathol 1992;16:969-74.
  7. Zimmerman R L, Fogt F. The β subunit of human chorionic gonadotropin lacks specificity for malignant cells in serous effusions. Modern Pathology 2004;17:701-4. doi:10.4172/1948-5956.1000147
  8. Ugurman F, Gozu A, Akkalyoncu B, et al. Pleural fluid and serum β-hcg levels and pleural fluıd/serum β-hcg ratio for the discrimination of malignant and benign pleural effusions. Solunum Hastalıkları 2003;14: 186-92.doi: 10.4103/0975-8844.106192

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

-

Authors

Burcak Erkol This is me

Fugen Aker This is me

Zeynep Gamze Kılıcoglu This is me

Basak Ustaalioglu This is me

Tarık Salman This is me

Publication Date

April 1, 2016

Submission Date

April 1, 2016

Acceptance Date

-

Published in Issue

Year 2016 Volume: 29 Number: 2

APA
Erkol, B., Aker, F., Kılıcoglu, Z. G., Ustaalioglu, B., & Salman, T. (2016). Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma. Marmara Medical Journal, 29(2), 127-130. https://doi.org/10.5472/MMJcr.2902.06
AMA
1.Erkol B, Aker F, Kılıcoglu ZG, Ustaalioglu B, Salman T. Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma. Marmara Med J. 2016;29(2):127-130. doi:10.5472/MMJcr.2902.06
Chicago
Erkol, Burcak, Fugen Aker, Zeynep Gamze Kılıcoglu, Basak Ustaalioglu, and Tarık Salman. 2016. “Serum β-Human Chorionic Gonadotropin As a Tumor Marker for Malignant Mesothelioma”. Marmara Medical Journal 29 (2): 127-30. https://doi.org/10.5472/MMJcr.2902.06.
EndNote
Erkol B, Aker F, Kılıcoglu ZG, Ustaalioglu B, Salman T (April 1, 2016) Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma. Marmara Medical Journal 29 2 127–130.
IEEE
[1]B. Erkol, F. Aker, Z. G. Kılıcoglu, B. Ustaalioglu, and T. Salman, “Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma”, Marmara Med J, vol. 29, no. 2, pp. 127–130, Apr. 2016, doi: 10.5472/MMJcr.2902.06.
ISNAD
Erkol, Burcak - Aker, Fugen - Kılıcoglu, Zeynep Gamze - Ustaalioglu, Basak - Salman, Tarık. “Serum β-Human Chorionic Gonadotropin As a Tumor Marker for Malignant Mesothelioma”. Marmara Medical Journal 29/2 (April 1, 2016): 127-130. https://doi.org/10.5472/MMJcr.2902.06.
JAMA
1.Erkol B, Aker F, Kılıcoglu ZG, Ustaalioglu B, Salman T. Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma. Marmara Med J. 2016;29:127–130.
MLA
Erkol, Burcak, et al. “Serum β-Human Chorionic Gonadotropin As a Tumor Marker for Malignant Mesothelioma”. Marmara Medical Journal, vol. 29, no. 2, Apr. 2016, pp. 127-30, doi:10.5472/MMJcr.2902.06.
Vancouver
1.Burcak Erkol, Fugen Aker, Zeynep Gamze Kılıcoglu, Basak Ustaalioglu, Tarık Salman. Serum β-human chorionic gonadotropin as a tumor marker for malignant mesothelioma. Marmara Med J. 2016 Apr. 1;29(2):127-30. doi:10.5472/MMJcr.2902.06